Omnicell, Inc. (NASDAQ:OMCL) Rating Reiterated by Piper Jaffray Companies

Omnicell, Inc. (NASDAQ:OMCL)‘s stock had its “hold” rating reaffirmed by Piper Jaffray Companies in a research report issued on Sunday, July 30th. They currently have a $40.00 target price on the stock. Piper Jaffray Companies’ price target points to a potential downside of 19.27% from the company’s previous close.

Other analysts have also issued reports about the company. Dougherty & Co increased their target price on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 target price (up from $43.00) on shares of Omnicell in a report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $53.00 target price (up from $43.00) on shares of Omnicell in a report on Tuesday, April 25th. TheStreet lowered Omnicell from a “b-” rating to a “c+” rating in a report on Thursday, May 4th. Finally, Craig Hallum increased their target price on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Omnicell currently has an average rating of “Buy” and a consensus target price of $49.00.

Shares of Omnicell (OMCL) opened at 49.55 on Friday. The stock has a 50 day moving average of $46.29 and a 200 day moving average of $41.70. The firm’s market cap is $1.86 billion. Omnicell has a 52 week low of $30.35 and a 52 week high of $51.97.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. During the same period in the prior year, the firm posted $0.38 EPS. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities analysts forecast that Omnicell will post $1.31 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/piper-jaffray-companies-reiterates-hold-rating-for-omnicell-inc-nasdaqomcl-updated-updated.html.

In other Omnicell news, Director Gary S. Petersmeyer sold 2,200 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $41.41, for a total value of $91,102.00. Following the completion of the transaction, the director now directly owns 21,075 shares in the company, valued at $872,715.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP J Christopher Drew sold 11,375 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $51.16, for a total value of $581,945.00. Following the completion of the transaction, the vice president now owns 139,201 shares of the company’s stock, valued at $7,121,523.16. The disclosure for this sale can be found here. Insiders sold 214,932 shares of company stock valued at $10,204,151 over the last quarter. Corporate insiders own 3.77% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue boosted its stake in shares of Omnicell by 3.0% in the first quarter. State of Alaska Department of Revenue now owns 4,080 shares of the company’s stock valued at $165,000 after buying an additional 120 shares during the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of Omnicell by 12.9% in the first quarter. Conestoga Capital Advisors LLC now owns 1,513,866 shares of the company’s stock valued at $61,539,000 after buying an additional 172,642 shares during the last quarter. SFE Investment Counsel bought a new stake in shares of Omnicell during the first quarter valued at $332,000. Legato Capital Management LLC boosted its stake in shares of Omnicell by 3,965.0% in the first quarter. Legato Capital Management LLC now owns 42,154 shares of the company’s stock valued at $1,037,000 after buying an additional 41,117 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Omnicell by 2.7% in the first quarter. Louisiana State Employees Retirement System now owns 15,100 shares of the company’s stock valued at $614,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 96.35% of the company’s stock.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

What are top analysts saying about Omnicell Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omnicell Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit